Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Sethera Therapeutics Unveils Breakthrough Enzymatic Platform for Next-Generation Peptide Drugs

By: Newsfile

Salt Lake City, Utah--(Newsfile Corp. - August 21, 2025) - Sethera Therapeutics today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of peer-reviewed results describing an enzymatic crosslinking platform that forges durable thioether "staples," locking peptides into drug-like cyclic architectures. The platform works across a broad range of substrates, including sequences built entirely from non-natural building blocks, delivering exceptional versatility, expanding accessible chemical space, and enabling the design of next-generation peptide therapeutics.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Radical-Based Enzymatic Technology: Sethera's breakthrough platform acts like a precise "molecular stapler," creating durable thioether "staples" that are chemically robust and protease-resistant - superior to traditional disulfide bonds found in natural peptides.
  • Controlled "Promiscuity" with Precision: The platform shows broad substrate scope, accepting non-natural building blocks (D-amino acids, -amino acids, N-methyl residues) while directing exactly where bonds form - expanding accessible chemical space for next-generation therapeutics.
  • PNAS Publication Validates Impact: Peer-reviewed results in Proceedings of the National Academy of Sciences demonstrate the technology's potential to lead the next wave of innovation in peptide therapeutics, directly connecting to GLP-1s, insulins, and natural hormone design.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/263354_figure1_550.jpg

Click image above to view full announcement.



About Sethera Therapeutics

Sethera Therapeutics is developing internal programs and collaborations that leverage its enzymatic macrocyclization platform to create more effective, stable, and deliverable peptide medicines. By opening vast new design space and offering precise architectural control, Sethera is positioned to help lead the next wave of innovation in peptide therapeutics.

Contacts:

Karsten Eastman, PhD, CEO
385-461-8528
bd@setheratx.com

Source: Sethera Therapeutics

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263354

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.